This Potsdam Startup is Transforming Obesity and Diabetes Care with AI-Powered Digital Treatment

Digital health company Oviva is accelerating its mission to transform chronic care — and it just secured major backing to do it.

The Potsdam based startup announced a €200 million Series D funding round, marking one of the largest recent raises in the region’s digital health sector. But beyond the headline number, the story is about scale, technology, and a new model of healthcare delivery.

Oviva provides fully reimbursed digital treatment programs for people living with obesity, type 2 diabetes, and hypertension. Instead of traditional in-clinic visits alone, patients use a medical app combined with real clinical support.

Doctors, dietitians, and care teams guide patients remotely through structured, evidence-based programs — all integrated into public healthcare systems.

The company’s approach blends human care with smart technology. AI-powered tools help clinicians personalize treatment, monitor progress, and intervene when needed. The result: scalable, structured care that aims to improve long-term health outcomes while reducing pressure on overstretched healthcare systems.

Oviva says it has already supported more than one million patients across Europe. Its programs are clinically validated and reimbursed by statutory health insurers, removing one of the biggest barriers to access: cost.

The new funding will help Oviva expand its reach, invest further in AI-driven capabilities, and grow its presence in existing and new markets. As chronic conditions continue to rise across Europe, the company is positioning itself as a key player in making large-scale, digital-first care the new standard.

In a healthcare system struggling with workforce shortages and rising demand, Oviva’s latest milestone signals something bigger: digital chronic care is moving from niche innovation to mainstream infrastructure.